<DOC>
	<DOCNO>NCT00610649</DOCNO>
	<brief_summary>Trial determine maximum tolerate dose ( MTD ) base safety tolerability MK-8777 ( Org 26576 , SCH 900777 ) participant major depressive disorder .</brief_summary>
	<brief_title>Trial Determine Maximum Tolerated Dose ( MTD ) Based Safety Tolerability , Org 26576 Participants With Major Depressive Disorder ( 174001/P05704/MK-8777-001 )</brief_title>
	<detailed_description>This randomize , placebo-controlled , safety tolerability study examine MK-8777 participant major depressive disorder . In Part I trial , four different cohort six participant receive multiple rise dos MK-8777 ( range 100 mg twice day [ BID ] 300 mg BID ) placebo 16 day . In Part 2 , new cohort participant randomly assign receive 100 mg BID MK-8777 , 400 mg BID MK-8777 , placebo . Following titration ( 3 day per step ) , participant maintain assign BID dose Day 27 , follow one day day ( QD ) dosing , total 28 day . There 11 treatment arm total Part 1 Part 2 ( see Interventions ) .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Female nonpregnant , nonlactating , use acceptable method birth control , childbearing potential ; diagnose current major depressive disorder either mild severe , evidence score least 9 20 Quick Inventory Depression Symptomatology Clinician Rated ( QIDSC ) ; antidepressant na√Øve ; able refrain use grapefruit contain product time admission last assessment perform discharge ; smoke less equal 10 cigarette equivalent daily . current primary Axis I disorder major depressive disorder ; history bipolar I II disorder , dysthymia , psychotic depression , psychotic disorder , posttraumatic stress disorder , borderline personality disorder , obsessive compulsive disorder , eat disorder ; duration current depressive episode longer 2 year screen ; history significant suicide attempt , pose current risk attempt suicide ; know human immunodeficiency virus ( HIV ) positive , positive hepatitis B surface antigen hepatitis A antibodies hepatitis C total antibody ; clinically significant concurrent endocrine , renal , respiratory , cardiovascular , hematological , immunological , cerebrovascular , neurological , malignancy , concurrent medical condition , history diabetes mellitus ; donation blood within 60 day prior anticipate first dose trial medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>randomize</keyword>
	<keyword>placebo control</keyword>
	<keyword>maximum tolerate dose</keyword>
</DOC>